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Purpose of the study
To determine the prevalence of GBV-C/HGV (HGV) infec-
tion in HIV-infected patients, to assess the possible influ-
ence of HGV on the course of HIV infection by assessment
of immunological and virological markers of progression
of HIV infection, and to carry out a preliminary investiga-
tion on the effect of HGV infection on quality of life in
HIV-infected patients.
Methods
Serum samples of 329 HIV-infected patients were investi-
gated at the AIDS Center of the Teaching Hospital Na
Bulovce, Prague, from 2002–2005. The aim was to assess
the presence of markers of HGV infection by semiquanti-
tative HGV PCR evaluation and anti-HGV antibodies by
ELISA testing. HIV viral load and CD4 count were tested
concurrently. The Spearman's test was used to rule out the
correlation of CD4 count and HIV viral load on HGV
infection. In a pilot study, 37 HIV-infected patients tested
on markers of HGV infection, were evaluated for the qual-
ity of life by the SEIQoL and Life Satisfaction Question-
naire (LSQ) during 2007. We compared 13 (35.1%) HGV-
infected patients and 26 (64.9%) patients without recent
HGV infection.
Summary of results
107 (32.5%) patients were positive on PCR HGV, 123
(37.4%) patients were positive on anti-HGV-ELISA, and
12 (3.6%) were positive on both markers. Both patients
with positive PCR HGV and with positive anti-HGV had
higher CD4 count. This fact was more significant in
patients without HAART. No statistically significant effect
of HIV viral load on HGV viremia or anti-HGV levels was
observed. Average values in SEIQoL were 7.17 in HGV-
positive and 5.93 in HGV-negative patients. LSQ values
were 242.23 in HGV-positive and 233.88 in HGV-nega-
tive patients.
Conclusion
No relationship between HGV infection and HIV viral
load was observed. Patients with present or past HGV
infection had higher CD4 count. This relation was more
apparent in patients without HAART therapy. Our results
are comparable with results of other studies, showing ben-
eficial effect of HGV infection on CD4 count in HIV-
infected patients. On QoL, there is a trend showing that
HGV co-infected patients tend to experience better quality
of life measured by SEIQoL and LSQ than those without
HGV co-infection.
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